Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872025 · ClinicalTrials.gov registry record · Early Phase 1
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
A Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating, sponsored by Laura Esserman.
- Active
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT02872025: Active Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating, sponsored by Laura Esserman.
NCT02872025 is a Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating that is active but no longer recruiting, run by Laura Esserman. The registered enrollment target is 42 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02872025, a Early Phase 1 study of Carcinoma, Intraductal, Noninfiltrating, is active but no longer recruiting, sponsored by Laura Esserman.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
Primary Outcome
To determine the maximum tolerated dose (MTD), and recommended dose for subsequent expansion cohort, of intralesionally administered pembrolizumab in patients with ductal carcinoma in situ (DCIS) of the breast.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Intralesional mRNA 2752
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2026-03-31 |
| Phase | Early Phase 1 |
What the registry record for NCT02872025 still lists
NCT02872025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Carcinoma, Intraductal, Noninfiltrating appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02872025 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02872025 about?
NCT02872025 is a clinical study titled "Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)". This is a study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to immunotherapy.
What is the current status of trial NCT02872025?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2016-12-12. Estimated completion is 2026-03-31.
What conditions does trial NCT02872025 study?
This clinical trial studies the following conditions: Carcinoma, Intraductal, Noninfiltrating.
What interventions are being tested in trial NCT02872025?
The interventions under investigation include: Pembrolizumab (DRUG), Intralesional mRNA 2752 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02872025?
This trial is sponsored by Laura Esserman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02872025 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02872025's enrollment target sits among peer trials
42 605th of 2000 higher than 1,379 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI